Clinical Value of Somatostatin Receptor Scintigraphy in the Management of Medullary Thyroid Carcinoma
#1299
Introduction: Medullary Thyroid Carcinoma (MTC) is a rare form of thyroid cancer. It represents 5 to 10 % of these cancers. MTC grows from specialized thyroid cells called para-follicular cells, or C-cells that secrete a hormone called calcitonin. Its prognosis is usually good. Recurrences can occur, requiring lifelong surveillance.
Aim(s): The aim of this study is to evaluate the clinical value of Somatostatin Receptor Scintigraphy (SRS) in the management of patients with MTC.
Materials and methods: Four patients (2 man, 2 women) aged 28-67 years underwent a total of five SRS. All these patients had a total thyroidectomy for MTC. SRS was requested during an assessment of post-operative extension in two cases, research of recurrence in two cases and therapeutic evaluation in the last case.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Khamla E
Authors: Khamla E, Ben Sellem D, Ben Slimene M,
Keywords: Medullary Thyroid Carcinoma, Somatostatin Receptor Scintigraphy, Management ,
To read the full abstract, please log into your ENETS Member account.